BCM
STLNW

Beryl Capital Management’s Starling Oncology Warrant STLNW Stock Holding History

Beryl Capital Management’s Portfolio STLNW Stock Details STLNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-24,481
Closed -$33K – 206
2021
Q1 		$33K Buy
+24,481
New +$45.4K ﹤0.01% 203

Other funds holding STLNW

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
KC
Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return
QGA
Q Global Advisors Fort Worth, Texas $157M AUM 29.28% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $62.7B AUM 29.77% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Beryl Capital Management's STLNW Position: Q2 2021 in Review

Beryl Capital Management sold out of Starling Oncology Warrant (STLNW) in Q2 2021, closing a stake of 24,481 shares — an estimated $33K sold.

Beryl Capital Management first reported a position in STLNW in Q1 2021 and held it in 1 quarter. The position peaked at $33K in Q1 2021. 26 funds tracked by Wall St. Rank hold STLNW as of Q2 2021.

  • Beryl Capital Management reported no remaining Starling Oncology Warrant position as of Q2 2021 after selling out during the quarter.
  • Beryl Capital Management sold 24,481 Starling Oncology Warrant shares in Q2 2021, an estimated $33K.
  • Beryl Capital Management first reported a position in Starling Oncology Warrant in Q1 2021 and held it in 1 quarter.
  • Beryl Capital Management's Starling Oncology Warrant position peaked at $33K in Q1 2021.
  • 26 funds tracked by Wall St. Rank held Starling Oncology Warrant as of Q2 2021.

Based on Beryl Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.